SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com - BofA Securities has maintained its Neutral rating and DKK375.00 price target on Novo Nordisk (CSE:NOVOb) (CSE:NOVOB) (NYSE:NVO) following competitor Eli Lilly (NYSE:LLY)’s Phase III oral GLP1 trial results.
The trial data showed Eli Lilly’s oral GLP1 Orforglipron achieved approximately 11% weight loss at 72 weeks in obese patients, which falls below Lilly’s expected 13-14% target and investor expectations.
BofA highlighted that these results compare favorably for Novo Nordisk’s oral Semaglutide 25mg, which demonstrated approximately 14% weight loss and is scheduled for launch in fiscal year 2026, calling it "an underappreciated opportunity."
The bank noted several remaining considerations including supply constraints for oral Semaglutide in higher-priced markets, differences in water/food effects between the competing products, and unclear pricing strategies between Novo Nordisk and Eli Lilly.
Despite the positive comparison to Lilly’s data, BofA maintained its Neutral stance on Novo Nordisk, noting that consensus estimates of approximately DKK3 billion in fiscal year 2026 sales for oral Semaglutide are "likely conservative" while acknowledging unclear short-term growth outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.